Want to see SABS full AI Analyst Report?
Top Page
SAB Biotherapeutics
(NASDAQ:SABS)
Select Model
Select Model
Rating:53Neutral
Price Target:
$3.00
▼(-22.68% Downside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weak financial performance—near-zero recent revenue and substantial ongoing cash burn despite a low-debt balance sheet. Technicals add some support with the stock trading above key moving averages and neutral RSI, while valuation appears low (P/E ~8.3) but is discounted due to business traction and cash-flow concerns.
Positive Factors
Low leverage
Very low leverage reduces fixed financial obligations and preserves flexibility while the company funds clinical development. The expanded equity and asset base also provides a stronger balance-sheet platform for partnerships, research investment, and managing operating volatility over the next several quarters.
Negative Factors
Revenue collapse
The collapse to effectively zero revenue indicates that SAB currently lacks dependable commercial or partnership revenue to support its cost base. Without a sustained recovery, the company remains dependent on new collaborations, grants, or financing, making future operating performance highly uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage reduces fixed financial obligations and preserves flexibility while the company funds clinical development. The expanded equity and asset base also provides a stronger balance-sheet platform for partnerships, research investment, and managing operating volatility over the next several quarters.
Read all positive factors
SAB Biotherapeutics (SABS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$271.14M
Dividend YieldN/A
Average Volume (3M)562.15K
Price to Earnings (P/E)0.8
Beta (1Y)0.98
Revenue Growth-100.00%
EPS Growth95.16%
CountryUS
Employees86
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3.57
Shares Outstanding90,986,370
10 Day Avg. Volume888,176
30 Day Avg. Volume562,149
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-93.60
Enterprise Value/Ebitda-22.65
Forecast
1Y Price Target
$12.67Price Target Upside226.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
SAB Biotherapeutics Business Overview & Revenue Model
Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product ca...
How the Company Makes Money
SAB Biotherapeutics makes money primarily through (1) collaboration and partnership revenue and (2) other sources such as grants or similar non-dilutive funding when applicable; product sales revenue is typically null or immaterial while the compa...
SAB Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 1.32M | 2.24M | 23.90M | 60.88M |
| Gross Profit | -2.28M | -3.08M | -3.47M | -1.51M | 20.61M | 59.22M |
| EBITDA | -9.43M | 16.60M | -28.99M | -38.13M | -15.12M | -15.20M |
| Net Income | -12.78M | 13.27M | -34.11M | -42.19M | -18.74M | -17.14M |
Balance Sheet | ||||||
| Total Assets | 238.21M | 172.81M | 44.20M | 83.94M | 50.90M | 81.14M |
| Cash, Cash Equivalents and Short-Term Investments | 102.63M | 96.59M | 20.76M | 56.57M | 15.05M | 33.21M |
| Total Debt | 5.13M | 5.95M | 4.67M | 5.91M | 5.93M | 8.52M |
| Total Liabilities | 23.43M | 21.32M | 18.23M | 26.64M | 19.85M | 42.59M |
| Stockholders Equity | 214.78M | 151.49M | 25.97M | 57.30M | 31.06M | 38.55M |
Cash Flow | ||||||
| Free Cash Flow | -72.70M | -45.71M | -34.63M | -25.32M | -25.63M | -8.96M |
| Operating Cash Flow | -68.21M | -44.78M | -34.29M | -25.12M | -23.46M | 1.99M |
| Investing Cash Flow | -267.75M | -121.71M | -11.96M | -152.70K | -2.09M | -10.94M |
| Financing Cash Flow | 350.85M | 168.30M | -1.17M | 66.77M | 1.05M | 35.89M |
SAB Biotherapeutics Technical Analysis
Negative
3.88
Price Trends
3.53
Negative
3.60
Negative
3.75
Negative
Market Momentum
-0.18
Positive
34.86
Neutral
21.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Negative. The current price of 3.88 is above the 20-day moving average (MA) of 3.23, above the 50-day MA of 3.53, and above the 200-day MA of 3.75, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 34.86 is Neutral, neither overbought nor oversold. The STOCH value of 21.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SABS.
SAB Biotherapeutics Risk Analysis
SAB Biotherapeutics disclosed 88 risk factors in its most recent earnings report. SAB Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SAB Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $90.38M | 2.15 | 68.56% | ― | -15.11% | ― | |
53 Neutral | $271.14M | 0.83 | -6.74% | ― | -100.00% | 95.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $32.87M | -0.68 | -175.46% | ― | ― | 59.14% | |
42 Neutral | $9.55M | -0.65 | -113.79% | 0.03% | -90.65% | 26.48% |
* Healthcare Sector Average
SABS
SAB Biotherapeutics
2.98
0.67
29.00%
LSTA
Lisata Therapeutics
1.06
-1.37
-56.38%
NXTC
NextCure
7.18
0.83
13.07%
RLYB
Rallybio
17.02
12.80
302.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.